Drug delivery systems for RNA therapeutics

被引:842
作者
Paunovska, Kalina
Loughrey, David
Dahlman, James E. [1 ]
机构
[1] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA
关键词
NORMAL ORGAN WEIGHTS; LIPID-LIKE NANOPARTICLES; MODIFIED MESSENGER-RNA; CHRONIC HEPATITIS-C; II-THE-BRAIN; IN-VIVO; ANTISENSE OLIGONUCLEOTIDES; SIRNA DELIVERY; POLYMERIC NANOPARTICLES; MOLECULAR-MECHANISMS;
D O I
10.1038/s41576-021-00439-4
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
RNA-based gene therapy requires therapeutic RNA to function inside target cells without eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug delivery systems, which circumvent the limitations of viral delivery vectors. Here, we review the growing number of RNA therapeutic classes, their molecular mechanisms of action, and the design considerations for their respective delivery platforms. We describe polymer-based, lipid-based, and conjugate-based drug delivery systems, differentiating between those that passively and those that actively target specific cell types. Finally, we describe the path from preclinical drug delivery research to clinical approval, highlighting opportunities to improve the efficiency with which new drug delivery systems are discovered. RNA therapies can be used to manipulate gene expression or produce therapeutic proteins. Here, the authors describe the growing number of RNA therapies and their molecular mechanisms of action. They also discuss the path from preclinical drug delivery research to clinical approval of these drugs.
引用
收藏
页码:265 / 280
页数:16
相关论文
共 257 条
[1]   mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].
A Feldman, Robert ;
Fuhr, Rainard ;
Smolenov, Igor ;
Ribeiro, Amilcar ;
Panther, Lori ;
Watson, Mike ;
Senn, Joseph J. ;
Smith, Mike ;
Almarsson, Orn ;
Pujar, Hari S. ;
Laska, Michael E. ;
Thompson, James ;
Zaks, Tal ;
Ciaramella, Giuseppe .
VACCINE, 2019, 37 (25) :3326-3334
[2]   Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza [J].
Abbott, Timothy R. ;
Dhamdhere, Girija ;
Liu, Yanxia ;
Lin, Xueqiu ;
Goudy, Laine ;
Zeng, Leiping ;
Chemparathy, Augustine ;
Chmura, Stephen ;
Heaton, Nicholas S. ;
Debs, Robert ;
Pande, Tara ;
Endy, Drew ;
La Russa, Marie F. ;
Lewis, David B. ;
Qi, Lei S. .
CELL, 2020, 181 (04) :865-+
[3]   A cytosine deaminase for programmable single-base RNA editing [J].
Abudayyeh, Omar O. ;
Gootenberg, Jonathan S. ;
Franklin, Brian ;
Koob, Jeremy ;
Kellner, Max J. ;
Ladha, Alim ;
Joung, Julia ;
Kirchgatterer, Paul ;
Cox, David B. T. ;
Zhang, Feng .
SCIENCE, 2019, 365 (6451) :382-+
[4]   C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector [J].
Abudayyeh, Omar O. ;
Gootenberg, Jonathan S. ;
Konermann, Silvana ;
Joung, Julia ;
Slaymaker, Ian M. ;
Cox, David B. T. ;
Shmakov, Sergey ;
Makarova, Kira S. ;
Semenova, Ekaterina ;
Minakhin, Leonid ;
Severinov, Konstantin ;
Regev, Aviv ;
Lander, Eric S. ;
Koonin, Eugene V. ;
Zhang, Feng .
SCIENCE, 2016, 353 (6299)
[5]   From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies [J].
Adachi, Hironori ;
Hengesbach, Martin ;
Yu, Yi-Tao ;
Morais, Pedro .
BIOMEDICINES, 2021, 9 (05)
[6]   Impact of Serum Proteins on the Uptake and RNA Interference Activity of N-Acetylgalactosamine-Conjugated Small Interfering RNAs [J].
Agarwal, Saket ;
Allard, Ruth ;
Darcy, Justin ;
Chigas, Samantha ;
Gu, Yongli ;
Nguyen, Tuyen ;
Bond, Sarah ;
Chong, Saeho ;
Wu, Jing-Tao ;
Janas, Maja M. .
NUCLEIC ACID THERAPEUTICS, 2021, 31 (04) :309-315
[7]   Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery [J].
Akinc, A ;
Lynn, DM ;
Anderson, DG ;
Langer, R .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (18) :5316-5323
[8]   The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs [J].
Akinc, Akin ;
Maier, Martin A. ;
Manoharan, Muthiah ;
Fitzgerald, Kevin ;
Jayaraman, Muthusamy ;
Barros, Scott ;
Ansell, Steven ;
Du, Xinyao ;
Hope, Michael J. ;
Madden, Thomas D. ;
Mui, Barbara L. ;
Semple, Sean C. ;
Tam, Ying K. ;
Ciufolini, Marco ;
Witzigmann, Dominik ;
Kulkarni, Jayesh A. ;
van der Meel, Roy ;
Cullis, Pieter R. .
NATURE NANOTECHNOLOGY, 2019, 14 (12) :1084-1087
[9]   Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms [J].
Akinc, Akin ;
Querbes, William ;
De, Soma ;
Qin, June ;
Frank-Kamenetsky, Maria ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Cantley, William L. ;
Dorkin, J. Robert ;
Butler, James S. ;
Qin, LiuLiang ;
Racie, Timothy ;
Sprague, Andrew ;
Fava, Eugenio ;
Zeigerer, Anja ;
Hope, Michael J. ;
Zerial, Marino ;
Sah, Dinah W. Y. ;
Fitzgerald, Kevin ;
Tracy, Mark A. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
de Fougerolles, Antonin ;
Maier, Martin A. .
MOLECULAR THERAPY, 2010, 18 (07) :1357-1364
[10]   Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].
Alberer, Martin ;
Gnad-Vogt, Ulrike ;
Hong, Henoch Sangjoon ;
Mehr, Keyvan Tadjalli ;
Backert, Linus ;
Finak, Greg ;
Gottardo, Raphael ;
Bica, Mihai Alexandru ;
Garofano, Aurelio ;
Koch, Sven Dominik ;
Fotin-Mleczek, Mariola ;
Hoerr, Ingmar ;
Clemens, Ralf ;
von Sonnenburg, Frank .
LANCET, 2017, 390 (10101) :1511-1520